Pregnancy: There are no data from the use of alglucosidase alfa in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown. Myozyme should not be used during pregnancy unless clearly necessary.
Breast-feeding: Alglucosidase alfa may be excreted in breast milk. Because there are no data available on effects in neonates exposed to alglucosidase alfa via breast milk, it is recommended to stop breastfeeding when Myozyme is used.
Fertility: There are no clinical data on the effects of alglucosidase alfa on fertility. Preclinical data did not reveal any significant adverse findings (see Pharmacology: Toxicology: Preclinical safety data under Actions).